CN102083463B - 编码甲病毒属复制酶的表达载体及其作为免疫佐剂的用途 - Google Patents

编码甲病毒属复制酶的表达载体及其作为免疫佐剂的用途 Download PDF

Info

Publication number
CN102083463B
CN102083463B CN200980118773.7A CN200980118773A CN102083463B CN 102083463 B CN102083463 B CN 102083463B CN 200980118773 A CN200980118773 A CN 200980118773A CN 102083463 B CN102083463 B CN 102083463B
Authority
CN
China
Prior art keywords
replicase
adjuvant
purposes according
expression vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980118773.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102083463A (zh
Inventor
K·克伊沃
R·斯库特
U·托茨
T·默尔多
A·门尼克
M·乌斯塔夫
K·卡尔德玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finnish Immunotechnology Ltd
Original Assignee
Finnish Immunotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finnish Immunotechnology Ltd filed Critical Finnish Immunotechnology Ltd
Publication of CN102083463A publication Critical patent/CN102083463A/zh
Application granted granted Critical
Publication of CN102083463B publication Critical patent/CN102083463B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980118773.7A 2008-05-23 2009-05-22 编码甲病毒属复制酶的表达载体及其作为免疫佐剂的用途 Expired - Fee Related CN102083463B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7189808P 2008-05-23 2008-05-23
US61/071,898 2008-05-23
PCT/EP2009/056240 WO2009141434A1 (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Publications (2)

Publication Number Publication Date
CN102083463A CN102083463A (zh) 2011-06-01
CN102083463B true CN102083463B (zh) 2017-04-05

Family

ID=40910781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980118773.7A Expired - Fee Related CN102083463B (zh) 2008-05-23 2009-05-22 编码甲病毒属复制酶的表达载体及其作为免疫佐剂的用途

Country Status (15)

Country Link
US (1) US9474800B2 (cg-RX-API-DMAC10.html)
EP (1) EP2296702A1 (cg-RX-API-DMAC10.html)
JP (1) JP5663474B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110044836A (cg-RX-API-DMAC10.html)
CN (1) CN102083463B (cg-RX-API-DMAC10.html)
AU (1) AU2009248735B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0913045A2 (cg-RX-API-DMAC10.html)
CA (1) CA2724570A1 (cg-RX-API-DMAC10.html)
IL (1) IL209077A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010012587A (cg-RX-API-DMAC10.html)
NZ (1) NZ589495A (cg-RX-API-DMAC10.html)
RU (1) RU2010152562A (cg-RX-API-DMAC10.html)
SG (1) SG191600A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009141434A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201007880B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
CN111304201B (zh) * 2020-02-21 2022-10-21 华南农业大学 一种降低乙型脑炎脑病毒感染的siRNA及其应用
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Rnaウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (en) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Method for creating divergent populations of nucleic acid molecules and proteins
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20060251620A1 (en) * 2002-08-22 2006-11-09 Lidia Ivanova Inducible alphaviral/orip based gene expression system
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2007342333B2 (en) * 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
WO2008065225A2 (es) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways;WOLFGANG W. LEITNER et al.;《NATURE MEDICINE》;20021223;第9卷(第1期);第33-39页 *

Also Published As

Publication number Publication date
JP2011523642A (ja) 2011-08-18
US9474800B2 (en) 2016-10-25
JP5663474B2 (ja) 2015-02-04
AU2009248735B2 (en) 2015-08-20
MX2010012587A (es) 2011-05-25
CN102083463A (zh) 2011-06-01
SG191600A1 (en) 2013-07-31
EP2296702A1 (en) 2011-03-23
BRPI0913045A2 (pt) 2017-05-23
CA2724570A1 (en) 2009-11-26
NZ589495A (en) 2012-06-29
US20110171255A1 (en) 2011-07-14
AU2009248735A1 (en) 2009-11-26
RU2010152562A (ru) 2012-06-27
ZA201007880B (en) 2012-02-29
WO2009141434A1 (en) 2009-11-26
KR20110044836A (ko) 2011-05-02
IL209077A0 (en) 2011-01-31
WO2009141434A4 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
US10329329B2 (en) Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
JP6717836B2 (ja) サイトメガロウイルス抗原およびその使用
CA2708668C (en) Vaccines against multiple subtypes of dengue virus
US9474800B2 (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
US20160215039A1 (en) Agents and methods based on the use of the eda domain of fibronectin
JP2003520597A (ja) 組換えフラビウイルスおよびその使用方法
CA2257137A1 (en) Synthetic hepatitis c genes
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム/ブーストワクチン用ウイルスベクター
JP2023523423A (ja) SARS-CoV-2に対するワクチン及びその調製物
KR102678519B1 (ko) Sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
Leng et al. Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice
US20250041386A1 (en) Recombinant Interleukin 12 Construct and Uses Thereof
KR102678544B1 (ko) Cd40 및 sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
WO2014151265A1 (en) Methods and compositions for stimulating immune response
EP1448223B1 (en) Thymosin augmentation of genetic immunization
US20250213671A1 (en) Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses
CA3141323C (en) Recombinant interleukin 12 construct and uses thereof
KR20170081646A (ko) 단순 포진 바이러스 유형 2(hsv-2)에 대한 면역 반응을 유도하기 위한 치료 조성물 및 방법
WO2007103565A2 (en) Wnv dna vaccine incorporating a cmv/r backbone and expressing wnv prm and e proteins
Vishanath DEEMED UNIVERSITY
HK1116831A (en) Flavivirus replicon constructs for tumour therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170405

Termination date: 20180522